WILL A RISKY EBOLA VACCINE REFUSED A US LICENSE IN 2015 BE APPROVED BY TRUMP’S FDA OR BE GIVEN TO AMERICANS UNDER NEW RIGHT TO TRY LAWS?


Sciencemag on the Merck vaccine.

On 31 July, the researchers announced that the trial was a stunning success: No one who received the vaccine developed the disease 10 days or more after the shot—presumably the length of time it takes to develop immunity. In the clusters that had to wait for the vaccine, 16 people contracted Ebola.

The unusual trial design yielded data that were not deemed strong enough to lead regulatory bodies to license the vaccine, but they went a long way toward convincing the world that an Ebola vaccine is at hand—and that it might have the power to prevent future outbreaks from ever becoming this big again.

http://www.sciencemag.org/news/2015/12/special-report-ebolas-thin-harvest

Comments are closed.

%d bloggers like this: